XOMA Corp. Stock
XOMA Corp. Stock
XOMA Corp. took a tumble today and lost -€1.000 (-4.550%).
XOMA Corp. is currently one of the favorites of our community with 10 Buy predictions and no Sell predictions.
Based on the current price of 21.6 € the target price of 65 € shows a potential of 200.93% for XOMA Corp. which would more than double the current price.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for XOMA Corp. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of XOMA Corp. in the next few years
Pros
?
C******** o* t** e**********
?
S********** s********
?
B****
Cons
?
G***** c******* t* c**********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of XOMA Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| XOMA Corp. | -4.550% | 6.931% | -3.571% | -5.263% | 0.000% | 9.091% | -29.504% |
| Biocryst Pharmaceuticals | 0.310% | 13.034% | 12.248% | -26.682% | -1.586% | -27.571% | -29.425% |
| Madrigal Pharmaceuticals inc. | -0.810% | -5.834% | -9.122% | 14.854% | -25.858% | 33.913% | 265.760% |
| Evolus Inc | -0.550% | 1.124% | -12.621% | -72.519% | -33.945% | -56.627% | -55.654% |
Comments
XOMA Royalty (NASDAQ:XOMA) had its "outperform" rating reaffirmed by analysts at Leerink Partners.
Show more
Ratings data for XOMA provided by MarketBeat
XOMA Royalty (NASDAQ:XOMA) had its "buy" rating reaffirmed by analysts at Benchmark Co..
Show more
Ratings data for XOMA provided by MarketBeat
XOMA Royalty (NASDAQ:XOMA) was given a new $45.00 price target on by analysts at Leerink Partners. They now have an "outperform" rating on the stock.
Show more
Ratings data for XOMA provided by MarketBeat